Physician profile

Robin A Hallquist

Family Medicine · Twin Mountain, NH

NPI 1386621134

$264.94

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$22.95

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $77.17 2021-2022
Inogen, INC. $38.37 2022
Astrazeneca Pharmaceuticals LP $29.99 2022
Abbvie INC. $27.22 2021-2022
Idorsia Pharmaceuticals US INC $22.95 2023 Quviviq
Glaxosmithkline, LLC. $19.51 2022
Biohaven Pharmaceutical Holding Company LTD. $19.29 2022
Lilly USA, LLC $15.75 2021
Pfizer INC. $14.69 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robin A Hallquist

$264.94

in general payments reported 2019-2025

Years
2021-2023
Top company
Novo Nordisk INC

https://glasscript.com/doctor/1114514/robin-a-hallquist

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.